Ramipril

angiotensin I converting enzyme ; Homo sapiens







272 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
101 14960504 Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). 2004 Feb 28 2
102 15025845 Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? 2004 Mar 1
103 15191027 Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. 2004 May 1
104 15222408 Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. 2004 Apr 1
105 15257162 Old antihypertensives and new diabetes. 2004 Aug 1
106 15353497 Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. 2004 Sep 14 1
107 15389235 Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES). 2004 Sep 1
108 15449961 Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective. 2004 1
109 15485399 The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. 2004 Nov 1
110 15485427 Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). 2004 Nov 1
111 12615747 The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. 2003 Mar 4 2
112 12628949 Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. 2003 Mar 11 2
113 12639174 Ramipril for the prevention and treatment of cardiovascular disease. 2003 Mar 3
114 12671332 The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned? 2003 Mar-Apr 1
115 12694342 Cardiovascular risk in patients with mild renal insufficiency. 2003 May 1
116 12708937 HOPE study impact on ACE inhibitors use. 2003 May 2
117 12729847 Prevention and management of chronic heart failure in patients at risk. 2003 May 8 1
118 12809971 Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study. 2003 Apr 2
119 12819323 The rationale and design of the AASK cohort study. 2003 Jul 1
120 12859160 Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. 2003 Jul 15 3
121 12911540 Mast cell infiltration and chemokine expression in progressive renal disease. 2003 Sep 1
122 12968195 Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure. 2003 Sep 1
123 13677258 [The status of atherosclerosis prevention in Austria]. 2003 2
124 14567371 Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. 2003 Oct 15 1
125 14625162 Recommendations for the management of special populations: racial and ethnic populations. 2003 Nov 1
126 15107595 Cardiovascular drugs and serum uric acid. 2003 Sep-Nov 2
127 11804984 Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. 2002 Jan 22 1
128 11835905 Angiotensin II and trials of cardiovascular outcomes. 2002 Jan 24 1
129 11835907 From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. 2002 Jan 24 2
130 11843949 Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. 2002 Jan 1
131 11843951 What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. 2002 Jan 1
132 11843952 Reducing the risk of stroke in diabetes: what have we learned that is new? 2002 Jan 1
133 11903350 A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study. 2002 Jan 1
134 11986905 Blockade of endothelial enzymes: new therapeutic targets. 2002 Mar 2
135 12025972 ACE inhibition and atherogenesis. 2002 Apr 2
136 12076194 Ramipril: a review of its use in the prevention of cardiovascular outcomes. 2002 2
137 12143014 [Parvovirus B19 myocarditis in a young man with previous non-bacterial meningitis]. 2002 Jul 26 1
138 12204499 Effect of long-term therapy with ramipril in high-risk women. 2002 Aug 21 2
139 12324991 Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. 2002 Sep-Oct 1
140 12423701 Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. 2002 Nov 15 2
141 14727978 Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. 2002 1
142 11276395 Recent clinical trial highlights in hypertension. 2001 Apr 1
143 11343399 Ask the doctor. Recently, I read that the ACE inhibitor ramipril is very good at preventing heart problems, particularly in people with diabetes. I'm diabetic, and for years I have been on a different ACE inhibitor (lisinopril). Should I be taking ramipril instead? 2001 Apr 1
144 11347755 Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. 2001 May 1
145 11381289 Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding? 2001 May 2
146 11446026 [Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study]. 2001 Jun 15 2
147 11465309 Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. 2001 1
148 11479247 Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. 2001 Jul 31 1
149 11496052 The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ? 2001 Sep 2
150 11581138 Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. 2001 Oct 2 2